AUPH — Aurinia Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $816.64m
- $578.47m
- $175.51m
- 63
- 29
- 28
- 35
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.318 | 50.1 | 45.6 | 134 | 176 |
Cost of Revenue | |||||
Gross Profit | — | — | 44.5 | 128 | 161 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 91.3 | 154 | 226 | 246 | 267 |
Operating Profit | -90.9 | -104 | -181 | -111 | -91.7 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -88.2 | -103 | -180 | -106 | -77.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -88.4 | -103 | -181 | -108 | -78 |
Net Income Before Extraordinary Items | |||||
Net Income | -88.4 | -103 | -181 | -108 | -78 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -88.4 | -103 | -181 | -108 | -78 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.95 | -0.867 | -1.4 | -0.762 | -0.545 |